Inventor · disambiguated record
Shunlin Ren
Also filed as: REN SHUNLIN
12 granted patents·26 pending applications·61 citations·filing 2002–2025
90Inventor score
Top patents by PatentIndex Score
38 records- 0195US10786517B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2019·Granted Sep 29, 2020·4 cites·14 claims
- 0290US10144759B2Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2016·Granted Dec 4, 2018·4 cites·15 claims
- 0389US9480692B2Sulfated-oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferationREN SHUNLIN·Filed 2015·Granted Nov 1, 2016·8 cites·22 claims
- 0489US8399441B2Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosisREN SHUNLIN·Filed 2010·Granted Mar 19, 2013·21 cites·5 claims
- 0588US11612609B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Mar 28, 2023·1 cites·21 claims
- 0688US9034859B2Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferationREN SHUNLIN·Filed 2012·Granted May 19, 2015·11 cites·11 claims
- 0784US11384115B2Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Jul 12, 2022·1 cites·20 claims
- 0884US10844089B2Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2018·Granted Nov 24, 2020·1 cites·6 claims
- 0983US2023310458A1Uses of oxygenated cholesterol sulfates (ocs)UNIV VIRGINIA COMMONWEALTH·Filed 2023·Application pending·0 cites
- 1082US9321802B2Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2013·Granted Apr 26, 2016·6 cites·2 claims
- 1181US10272097B2Uses of oxygenated cholesterol sulfates (OCS)UNIV VIRGINIA COMMONWEALTH·Filed 2014·Granted Apr 30, 2019·3 cites·18 claims
- 1279US11406646B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 1378US12226423B2Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2022·Granted Feb 18, 2025·0 cites·20 claims
- 1476US2020157140A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2019·Application pending·0 cites
- 1575US2023372361A1Use of oxygenated cholesterol sulfates for treating inflammatory conditionsDURECT CORP·Filed 2021·Application pending·0 cites
- 1674US2023233580A1Use of oxygenated cholesterol sulfates for cancers and non-cancerous transformations related to epstein-barr virusDURECT CORP·Filed 2021·Application pending·0 cites
- 1774US2023285416A1Use of oxygenated cholesterol sulfates for treating at least one of insulin resistance, diabetes, and prediabetesDURECT CORP·Filed 2021·Application pending·0 cites
- 1874US2023293551A1Use of oxygenated cholesterol sulfates for treating autoimmune conditionsDURECT CORP·Filed 2021·Application pending·0 cites
- 1974US2022054505A1Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue RegenerationUNIV VIRGINIA COMMONWEALTH·Filed 2021·Application pending·0 cites
- 2074US2023218639A1Use of oxygenated cholesterol sulfates for treating neurological conditions, neurodegenerative diseases, and addictionDURECT CORP·Filed 2021·Application pending·0 cites
- 2172US2021238219A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 2268US2020138831A1Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorderUNIV VIRGINIA COMMONWEALTH·Filed 2019·Application pending·0 cites
- 2367US2007275939A1Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosisREN SHUNLIN·Filed 2007·Application pending·0 cites
- 2466US2025249021A1Compositions Comprising 5-Cholesten-3, 25-Diol, 3-Sulfate (25HC3S) or Pharmaceutically Acceptable Salt Thereof And at Least One Cyclic OligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2025·Application pending·0 cites
- 2564US2020009158A1Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue RegenerationUNIV VIRGINIA COMMONWEALTH·Filed 2019·Application pending·0 cites
- 2664US2019135856A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2018·Application pending·0 cites
- 2763US2021161913A1Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorderUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 2862US2018127457A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 2961US2015072962A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2013·Application pending·0 cites
- 3059US2021169902A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2020·Application pending·0 cites
- 3158US2016355544A1Novel cholesterol metabolite, 5-cholesten, 3beta-25-diol, disulfate (25hcds) for therapy of metabolic disorders, hyperlipidemia, diabetes, fatty livers diseases and atherosclerosisUNIV VIRGINIA COMMONWEALTH·Filed 2016·Application pending·0 cites
- 3256US2017136038A1Sulfated-Oxysterol and Oxysterol Sulfation by Hydroxysterol Sulfotransferase Promote Lipid Homeostasis and Liver Tissue RegenerationREN SHUNLIN·Filed 2016·Application pending·0 cites
- 3355US2019374554A1Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesionsUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 3454US2023141965A1Treatment of infectious diseasesDURECT CORP·Filed 2021·Application pending·0 cites
- 3554US2019083509A1Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorderUNIV VIRGINIA COMMONWEALTH·Filed 2018·Application pending·0 cites
- 3651US2019269695A1Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharideUNIV VIRGINIA COMMONWEALTH·Filed 2017·Application pending·0 cites
- 3746US2017252355A1Oxygenated cholesterol sulfates for therapy of disorders caused by at least one of attenuated leptin activity and a lipid storage disorderUNIV VIRGINIA COMMONWEALTH·Filed 2015·Application pending·0 cites
- 3839US2003092092A1Antitryptase autoantibody-tryptase immune complex as a unique marker for diagnosis and as a potential target for therapy of immediate hypersensitivity diseasesPAX BIOGEN CO LTD·Filed 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Shunlin Ren files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →